Back to Search
Start Over
Treatment Outcome of Angiocentric T-cell and NK/T-cell Lymphoma, Nasal Type: Radiotherapy Versus Chemoradiotherapy
- Source :
- Japanese Journal of Clinical Oncology. 35:1-5
- Publication Year :
- 2005
- Publisher :
- Oxford University Press (OUP), 2005.
-
Abstract
- Objective The purpose of this study was to evaluate the treatment outcome of angiocentric T-cell and natural killer (NK)/T-cell lymphoma, nasal type. Methods Between February 1989 and March 2001, 53 patients with newly diagnosed angiocentric T-cell and NK/T-cell lymphoma, nasal type involving the head and neck, were treated with radiation therapy (RT). There were 37 males and 16 females. The median age of the patients was 45 years (range 19-73). Twenty of them were treated with chemoradiotherapy (CRT), while 33 with treated with RT alone. The median follow-up period was 74 months (range 6-173). Results The 5-year overall survival rate of all patients was 69%. CRT appeared to be inferior to RT alone in terms of 5-year overall survival, though the difference was not statistically significant (59 versus 76%, P = 0.27). Conclusions There was no difference in survival between RT and CRT in angiocentric T-cell and NK/T-cell lymphoma, nasal type.
- Subjects :
- Adult
Male
Cancer Research
medicine.medical_specialty
medicine.medical_treatment
T cell
Nose Neoplasms
Treatment outcome
Lymphoma, T-Cell
Gastroenterology
Immunophenotyping
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Humans
Medicine
T-cell lymphoma
Radiology, Nuclear Medicine and imaging
Head and neck
Aged
business.industry
Radiotherapy Dosage
General Medicine
Nasal type
Middle Aged
medicine.disease
Combined Modality Therapy
Lymphoma
Surgery
Killer Cells, Natural
Survival Rate
Radiation therapy
Treatment Outcome
medicine.anatomical_structure
Oncology
Female
business
Chemoradiotherapy
Subjects
Details
- ISSN :
- 14653621
- Volume :
- 35
- Database :
- OpenAIRE
- Journal :
- Japanese Journal of Clinical Oncology
- Accession number :
- edsair.doi.dedup.....484c19d31f68e610b2b631fa94a026da